CSL to Invest Approximately 1.5 Billion in U.S. to Manufacture Plasma-Derived Therapies

If you and your employer have already experimented with a distributed team, you know that many of the major concerns around remote work — compromised productivity, camaraderie and accountability — were grossly overstated and easily checked. But the question of how to maintain a happy remote team — that takes a lot of care and intentionality.

Experts from the world’s leading plasma companies have come together to create a new alliance aimed at treating the new coronavirus. Partners include CSL Behring, the third largest biotech company globally, currently underway with a 1.8 million SF expansion of its Kankakee, Illinois, production site.

Change is the universe’s default. Progress, at its best, is positive change. As we together weather the unprecedented global reverberations presented by the novel coronavirus (COVID-19) pandemic, subsequent shelter-in-place precautions, and tremendous personal and business losses, it is tempting to abandon the notion of progress. But that would be a tragic mistake.